TÀI LIỆU THAM KHẢO

1. Jeremy Levy. (2009). Hemodialysis Presciption. Jeremy Levy. Third Edition. Oxford handbook of dialysis. Oxford University Press.

2. Bach Nguyen, Fukuuchi. Survival Rates and Causes of death in Vietnamese Chronic Hemodialysis patients. Renal Replacement Therapy (2017): 3: 22, DOI 10, 1186/s41100-17-0099-6.

3. KDOQI clinical practice guideline for hemodialysis adequacy. Update. Am J Kidney Dis. 2015;66(5):884-93

4. Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int. 2022;42(2):110-153.

5. Szeto CC, Li PK. Peritoneal dialysis-associated peritonitis. Clin J Am Soc Nephrol. 2019;14(7):1100-1105.

6. Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int. 2011;31(6):614-630.

7. Bethany Roehm, Gaurav Gulati, Daniel E. Weiner. Heart Failure Management in Dialysis Patients: Many Treatment Options with No Clear Evidence. Semin Dial. 2020 May ; 33(3): 198-208. doi:10.1111/sdi.12878.

8. Bộ Y tế. Thải ghép thận cấp. Hướng dẫn chẩn đoán và điều trị một số bệnh về thận tiết niệu 2015: 194-202.

9. Hội ghép tạng Việt nam. Hướng dẫn ghép thận Việt nam. Nhà xuất bản Y học 2017.

10. Donavitch GM. Handbook of Kidney Transplantation, 5thEdition, 2010.

11. KDIGO. Clinical practice guideline for the care of kidney transplant recipients, 2009.

12. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60- 69.

13. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease-a systematic review and meta-analysis. PLoS One. 2016;11: e0158765.

14. McCullough PA, Bakris GL, Owen WF Jr, et al. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004;148:243-251.

15. Haase M, Muller C, Damman K, et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:99-11

16. Skrabic R, Kumric M, Vrdoljak J, et al. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. Biomedicines. 2022;10(10):2458. Published 2022 Oct 1. doi:10.3390/biomedicines10102458

17. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.

18. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.

19. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55.

20. Sosnov J, Lessard D, Goldberg RJ, Yarzebski J, Gore JM. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 2006;47:378-84.

21. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Sarnak et al. JACC VOL. 74, NO. 14, 2019 CKD and Coronary Artery Disease: A KDIGO Confe rence Report OCTOBER 8, 2019:1823 - 3 8 1836 Registry of Myocardial Infarction. Circulation 2007;116:1465-72.

22. Acharya, Tushar, Huang, Jian, Tringali, Christopher R et al. Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study); American Journal of Cardiology, 647-655.

23. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: Cross-sectional study. Atherosclerosis 2004;172:95-105 

24. Suhail Allaqaband, Fuad Jan, Tanvir Bajwa. Endovascular Treatment of Peripheral Vascular Disease. Curr Probl Cardiol 2009;34:359-476.

25. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317-1324.

26. McLafferty RB, Dunnington GL, Mattos MA, et al. Factors affecting the diagnosis of peripheral vascular disease before vascular surgery referral. J Vasc Surg 2000;31:870-879.

27. Belch J, Topol E, Agnelli G, Bertrand M. Critical issues in peripheral arterial disease detection and management. Arch Intern Med 2003;163:884-92.

28. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl1):S1-S266.

29. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150.

30. American Diabetes Association. Standards of medical care in diabetes--2019. Diabetes Care. 2019;42(Suppl 1):S90-S102.

31. Perazella MA. Drug-induced acute kidney injury: diverse mechanism of tubular injury. Current Opinion in Critical Care. 2019;25(6):550-570.

32. Perazella MA. Drug-induced acute interstitial nephritis. Expert Opin Drug Saf. 2005;4(4):723-731.

33. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diureticsangiotensin converting enzyme inhibitors, and angiotensin receptor blockers with NSAID and risk of acute kidney injury: nestled case-control study. BMJ. 2013;346:e8525.

34. Davenport MS, Perazella MA, Yee J, et al. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294(3):660-668. doi:10.1148/radiol.2019192094

35. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-c184. doi:10.1159/000339789

36. Macdonald DB, Hurrell C, Costa AF, et al. Canadian Association of Radiologists Guidance on Contrast Associated Acute Kidney Injury. Can Assoc Radiol J.2022;73(3):499-514. doi:10.1177/08465371221083970

37. Wintermark M, Sanelli PC, Albers GW, et al. Imaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery. AJNR Am J Neuroradiol 2013; 34:E117.

38. Keberle M, Tschammler A, Hahn D. Single-bolus technique for spiral CT of laryngopharyngeal squamous cell carcinoma: Comparison of different contrast material volumes, flow rates, and start delays. Radiology 2002; 224:171.

39. Yamashita Y, Komohara Y, Takahashi M, et al. Abdominal helical CT: evaluation of optimal doses of intravenous contrast material--a prospective randomized study. Radiology 2000; 216:718

40. Fayad LM, Bluemke DA, Fishman EK. Musculoskeletal imaging with computed tomography and magnetic resonance imaging: when is computed tomography the study of choice? Curr Probl Diagn Radiol 2005; 34:220.

41. Schieda N, Blaichman JI, Costa AF, et al. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can J Kidney Health Dis.2018;5:2054358118778573. Published 2018 Jun 12. doi:10.1177/2054358118778573

42. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation (2020)

43. Stevens L.A., Nolin T.D., Richardson M.M. và cộng sự. (2009). Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis, 54(1), 33-42.

44. Munar M.Y. và Singh H. (2007). Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician, 75(10), 1487-1496.

45. Matzke G.R., Aronoff G.R., Atkinson A.J. và cộng sự. (2011). Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 80(11), 1122-1137.

46. Demirovic J.A., Pai A.B., và Pai M.P. (2009). Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm, 66(7), 642-648.

47. Winter M.A., Guhr K.N., và Berg G.M. (2012). Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy, 32(7), 604-612.

48. Salazar D.E. và Corcoran G.B. (1988). Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med, 84(6), 1053-1060.

49. Cockcroft D.W. và Gault M.H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron, 16(1), 31-41.

50. Venkatachalam M.A., Griffin K.A., Lan R. và cộng sự. (2010). Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol, 298(5), F1078-1094.

51. He L., Wei Q., Liu J. và cộng sự. (2017). AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int, 92(5), 1071-1083.

52. Doi K., Nishida O., Shigematsu T. và cộng sự. (2018). The Japanese clinical practice guideline for acute kidney injury 2016. Clin Exp Nephrol, 22(5), 985-1045.

53. Hapca S., Siddiqui M.K., Kwan R.S.Y. và cộng sự. (2021). The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. Journal of the American Society of Nephrology, 32(1), 138.

54. Hsu R.K. và Hsu C. (2016). THE ROLE OF ACUTE KIDNEY INJURY IN CHRONIC KIDNEY DISEASE. Semin Nephrol, 36(4), 283-292.

55. Levey A.S., Atkins R., Coresh J. và cộng sự. (2007). Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int, 72(3), 247-259.

56. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International (2021):100, S96-S98

57. Pugh-Clarke K., Donlon S., và McCann M. (2010). CE: continuing education article. Prevention of infection in patients with chronic kidney disease part 1: application of infection control principles to the renal care environment. J Ren Care, 36(4), 191-198.

58. Stevens P.E., Levin A., và Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013). Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med, 158(11), 825-830.

59. Descamps-Latscha B., Jungers P., và Witko-Sarsat V. (2002). Immune system dysregulation in uremia: role of oxidative stress. Blood Purif, 20(5), 481-484.

60. Donlon S., Redmond A., McCann M. và cộng sự. (2011). Prevention of infection in patients with chronic kidney disease part III: surveillance and auditing in a renal care environment. J Ren Care, 37(3), 167-173.

61. Redmond A., Donlon S., Boyle G. và cộng sự. (2011). Prevention of infection in patients with chronic kidney disease. Part II: healthcare-associated infections. J Ren Care, 37(1), 52-62.

62. Ma B.M., Yap D.Y.H., Yip T.P.S. và cộng sự. (2021). Vaccination in patients with chronic kidney disease-Review of current recommendations and recent advances. Nephrology (Carlton), 26(1), 5-11.

63. Hội Tim Mạch học quốc gia Việt nam (2022), Khuyến cáo của phân hội Tăng huyết áp - Hội tim mạch quốc gia Việt Nam (VSH/VNHA) về chẩn đoán & điều trị tăng huyết áp

64. Dan Pugh, Peter J. Gallacher, Neeraj Dhaun, Management of Hypertension in Chronic Kidney Disease, Drugs (2019) 79:365-379

65. Dhaybi OA, Bakris G. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017;26:50-55

66. Rajiv Agarwal, Peter Kolkhof, George Bakris. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine, European Heart Journal (2021) 42, 152-161

67. Ashraf Mikhail, Christopher Brown, Jennifer Ann Williams et al: Renal Association Clinical Practice Guideline - Anaemia of Chronic Kidney Disease, BMC Nephrol. 2017 Nov 30;18(1):345. doi: 10.1186/s12882-017-0688-1

68. Jose Portoles, Leyre Martin et al: Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents, Front Med. 2021 Mar 26;8:642296. doi: 10.3389/fmed.2021.642296

69. Kerry Willis, PhD et KDIGO Staff: KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease, Kidney International Supplements (2012), vol 2, iss 4

70. Steven Fishbane, Stephen Brunton: Improving Detection and Management of Anemia in CKD, J Fam Pract. 2022 Jul;71(6 Suppl):S23-S28. doi: 10.12788/jfp.0411

71. Jodie l Babitt, Michele L Eisenga, Volker H Haase et al: Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference, Kidney Int. 2021 Jun;99(6):1280-1295. doi: 10.1016/j.kint.2021.03.020. Epub 2021 Apr 8.

72. Steven Fishbane, Bruce Spinowitz: Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018, Am J kidney Dis. 2018 Mar;71(3):423-435. doi: 10.1053/j.ajkd.2017.09.026. Epub 2018 Jan 11.

73. Hướng dẫn chẩn đoán và điều trị Đái tháo đường type 2- 2020- Bộ Y tế 

74. Nuha A Elsayed, Grazia Aleppo, Vanita R Aroda et al: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023, Diabetes Care 2023;46(Supplement_1): S191-S202

75. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int (2022): 102, pp. S1-S127.

76. William G. Herrington, Andrew H. Frankel et al: UKKA guideline_SGLT2i in adults with kidney disease v1 20.10.21, UKKA 28 September, 2021

77. 2018 AHA/ACC/ AACVPR/ AAPA/ABC/ ACPM/ ADA/ AGS/ APhA/ASPC/NLA/ PCNA Guideline on the Management of Blood Cholesterol

78. Kiểm soát Lipid máu trong phòng ngừa bệnh tim mạch do xơ vữa động mạch 2020 - tim mạch học

79. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

80. 2022 Taiwan lipid guidelines for primary prevention

81. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology

82. KDIGO 2017. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD- MBD). Kidney International Supplements. Vol 1. Issue 1.

83. Brenner & Rector’s The Kidney 2016. Elsevier, Tenth Edition.

84. Comprehensive Clinical Nephrology 2019. Elsevier, Sixth Edition.

85. Schrier's Diseases of The Kidney 2019. Ninth Edition.Volume 2

86. KDIGO 2012. Clinical practice guideline for acute kidney injury. Kidney International Supplements. Vol 2. Issue 1.

87. Garthwaite, E., Reddy, V., Douthwaite, S. et al. Clinical practice guideline management of blood-borne viruses within the hemodialysis unit. BMC Nephrol 20, 388 (2019). https://doi.org/10.1186/s12882-019-1529-1

88. John T. Daugirdas and al, “Infectious Disease”, Handbook of Dialysis, 5th Edition (2015), Wolters Kluwer.

89. Kidney Disease: Improving Global Outcomes (KDIGO) (2008). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney international. Supplement, (109), S1-S99. https://doi.org/10.1038/ki.2008.81.

90. Shah, AS, Amarapurkar, DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018; 38: 23- 32. https://doi.org/10.1111/liv.13498

91. Martin, P., Awan, A. A., Berenguer, M. C., Bruchfeld, A., Fabrizi, F., Goldberg, D. S., Jia, J., Kamar, N., Mohamed, R., Pessôa, M. G., Pol, S., Sise, M. E., Balk, E. M., Gordon, C. E., Adam, G., Cheung, M., Earley, A., & Jadoul, M. (2022). Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International, 102(6), 1228-1237. https://doi.org/10.1016/j.kint.2022.07.012

92. Chan CT, Blankestijn PJ, Dember LM, et al. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;96(1):37-47. doi:10.1016/j.kint.2019.01.017

93. Ku E, McCulloch CE, Johansen KL. Starting Renal Replacement Therapy: Is It About Time?. Am J Nephrol. 2019;50(2):144-151. doi:10.1159/000501510

94. Yu MK, O'Hare AM, Batten A, et al. Trends in Timing of Dialysis Initiation within Versus Outside the Department of Veterans Affairs. Clin J Am Soc Nephrol. 2015;10(8):1418-1427. doi:10.2215/CJN.12731214

95. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609-619. doi:10.1056/NEJMoa1000552

96. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011 Jul;80(1):17-28

97. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012 Jan 14;379(9811):165-80. doi: 10.1016/S0140-6736(11)60178-5. Epub 2011 Aug 15. PMID: 21840587.

98. García-Maset R, Bover J, Segura de la Morena J, Goicoechea Diezhandino M, Cebollada Del Hoyo J, Escalada San Martin J, Fácila Rubio L, Gamarra Ortiz J, García- Donaire JA, García-Matarín L, Gràcia Garcia S, Isabel Gutiérrez Pérez M, Hernández Moreno J, Mazón Ramos P, Montađés Bermudez R, Muđoz Torres M, de Pablos- Velasco P, Pérez-Maraver M, Suárez Fernández C, Tranche Iparraguirre S, Luis Górriz J. Information and consensus document for the detection and management of chronic kidney disease. Nefrologia (Engl Ed). 2022 May-Jun;42(3):233-264.

99. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3S):S1-S87.

100. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-1324

101. Martinez YV, Benett I, Lewington AJP, Wierzbicki AS; Guideline Committee. Chronic kidney disease: summary of updated NICE guidance. BMJ. 2021 Sep 6;374:n1992

102. National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:19-62

103. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med. 2011 Nov;124(11):1073-80

104. Liu P, Quinn RR, Oliver MJ, Ronksley PE, Hemmelgarn BR, Quan H, Hiremath S, Bello AK, Blake PG, Garg AX, Johnson J, Verrelli M, Zacharias JM, Abd ElHafeez S, Tonelli M, Ravani P. Association between Duration of Predialysis Care and Mortality after Dialysis Start. Clin J Am Soc Nephrol. 2018 Jun 7;13(6):893-899

105. Isnard Bagnis C, Crepaldi C, Dean J, Goovaerts T, Melander S, Nilsson EL, Prieto- Velasco M, Trujillo C, Zambon R, Mooney A. Quality standards for predialysis education: results from a consensus conference. Nephrol Dial Transplant. 2015 Jul;30(7):1058-66

106. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K. An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis. 2001 Nov;38(5):1122-8

107. Saggi SJ, Allon M, Bernardini J, Kalantar-Zadeh K, Shaffer R, Mehrotra R; Dialysis Advisory Group of the American Society of Nephrology. Considerations in the optimal preparation of patients for dialysis. Nat Rev Nephrol. 2012 Apr 10;8(7):381-9

108.Vachharajani TJ, Hassanein M, Liaqat A, Haddad N. Vessel Preservation in Chronic Kidney Disease Adv Chronic Kidney Dis. 2020 May;27(3):177-182

109. Davidson S. Supportive care in advanced chronic kidney disease. In Brenner and Rector’s The Kidney, Elsevier, 11thed, Ch 62, Vol 2, p 2015-2037

110. Varkey B. Principles of Clinical Ethics and Their Application to Practice. Med Princ Pract. 2021;30(1):17-28

111. Schell OJ, Arnold RM, Davison S. Uptodate 2023- Kidney palliative care: Conservative kidney management

112. Sijpkens YW, Berkhout-Byrne NC, Rabelink TJ. Optimal predialysis care. NDT Plus. 2008 Oct;1(Suppl 4):iv7-iv13

113. McCullough PA, Kellum JA, Haase M, et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:82-98

114. American Diabetes Association (2022). Chapter 11: Chronic kidney disease and Risk management. In: Standards of Medical Care in Diabetes-2022, Diabetes Care (2022); 45(Suppl.1), S175-S184. https://doi.org/10.2337/dc22-S011

115. De Boer IH, Khunti K, Sadusky T, et al. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). https://doi.org/10.2337/dci220027.

116. Fornoni A., Nelson R., Najafian B., et al. (2020), “Chapter 39 : Epidemiology of Diabetic kidney disease”, In: Yu A.S.L. et al. (eds), Brenner & Rectors’s THE KIDNEY, 11thedition, pp. 1327-1379, Elsevier.

117. Tong L.L., Adler S., Wanner C. (2019), “Prevention and treatment of Diabetic kidney disease”. In: Feehally J., Floege J., Tonelli M., Johnson R. (eds), Comprehensive clinical nephrology, 6th edition, pp. 376- 384, Elsevier

118. Bajema IM, Wilhelmus S, Alpers CE, et al. “Revision of the International Society of Nephrology /Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices”, Kidney Int 2018, 93, pp. 789 - 796.

119. Fanouriakis A, Kostopoulou M, Cheema K, et al. “2019 Update of the joint European League Against Rheumatism and European Renal Association - European Dialysis and Transplantation Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis” Ann Rheum Dis 2020, 79, pp. 713 - 723.

120. Huỳnh Ngọc Phương Thảo. “Đánh giá chỉ số hoạt động, mạn tính NIH trong viêm thận do lupus”. Y học TP Hồ Chí Minh (2018), Phụ bản tập 22, số 2: tr. 277 - 283.

121. Kostopoulou M, Fanouriakis A, Cheema K, et al. “Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association - European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations”. RMD Open 2020: 6, e001263.

122. Radhakrishnan J, Appel GB, D’Agati V, et al. “Systemic Lupus Erythematosus”. In: Yu A, et al. eds. Brenner & Rector’s THE KIDNEY, Elsevier 2020, pp. 1092 - 1106. 

123. Wadhwani S, Jayne D, Rovin BH, et al. “Lupus nephritis”. In: Feehally J et al. eds, Comprehensive clinical nephrology, 6thedition, Elsevier 2019, pp. 306 - 319.

124. Feehally J, Floege J. “Immunoglobulin A Nephropathy and IgA Vasculitis (Henoch Schonlein purpura)”. In: Feehally J et al. eds, Comprehensive clinical nephrology, 6thedition, Elsevier 2019, pp. 270 - 280.

125. Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017; 318: 432 - 442.

126. Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis: 2009; 53: 26 - 32.

127. Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009; 24: 3694 - 3701.

128. Saha MK, Pendergraft III WF, Jennett JC et al. “Chapter 31: Primary glomerular disease”. In: Yu A, et al. eds. Brenner & Rector’s THE KIDNEY, Elsevier 2020, pp. 1007 - 1091.

129. Lionaki, S., Mantios, E., et al. (2021). Clinical Characteristics and Outcomes of Adults with Nephrotic Syndrome Due to Minimal Change Disease. Journal of clinical medicine, 10(16), 3632. https://doi.org/10.3390/jcm10163632

130. Xue, C., Yang, B., et al. (2020). Efficacy and safety of rituximab in adult frequent- relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clinical kidney journal, 14(4), 1042-1054. https://doi.org/10.1093/ckj/sfaa191

131. Rosenberg, A. Z., & Kopp, J. B. (2017), Focal Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 12(3), 502-517.

132. Zand, L., Glassock, R. J., et al (2017), What are we missing in the clinical trials of focal segmental glomerulosclerosis? European Dialysis and Transplant Association - European Renal Association, 32(1), i14-i21.

133. Couser W. G. (2017). Primary Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 12(6), 983-997.

134. Sethi S. (2021). New 'Antigens' in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 32(2), 268-278.

135. Kanjanabuch T., Kittikowit W., et al. (2009). An update on acute postinfectious glomerulonephritis worldwide. Nature reviews. Nephrology, 5(5), 259-269.

136. ANCA Glomerulonephritis and Vasculitis, Jennette, J. Charles; Nachman, Patrick H. Clinical Journal of the American Society of Nephrology 12(10):p 1680-1691, October 2017. | DOI: 10.2215/CJN.02500317

137. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease, Casal Moura, Marta; Irazabal, Maria V.; Eirin, Alfonso, JASN 31(11):p 2688-2704, November 2020. | DOI: 10.1681/ASN.2019111197

138. William F.Pendergraft, Patrick H.Nachman, J.Charles Jannette, Ronald J.Falk: Pauci- Immune Crescentis Glomerulonephritis Disease, Brenner and Rector’s the Kidney, vol 1, Elsevier(2016), chapter 32, p 1081- 1089.

139. Agnes B. Fogo, Mark A. Lusco, Behzad Najafian, and Charles E. Alpers: AJKD Atlas of Renal Pathology: Pauci-immune Necrotizing Crescentic Glomerulonephritis. Am J Kidney Dis.2016;68(5):e29-e30.

140. Van Daalen, Emma E.; Jennette, J. Charles; McAdoo, Stephen P. Et al: Predicting Outcome in Patients with Anti-GBM Glomerulonephritis, Clinical Journal of the American Society of Nephrology 13(1):p 63-72, January 2018. | DOI: 10.2215/CJN.04290417

141. William F.Pendergraft, Patrick H.Nachman, J.Charles Jannette, Ronald J.Falk: Anti-Glomerular Basement membrane Glomerulonephritis, Brenner and Rector’s the Kidney, vol 1, Elsevier(2016), chapter 32, p 1076-1081.

142. Richard G. Phelps, A. Neil Turner: Anti-Glomerular Basement Membrane Disease and Goodpasture Disease. Comprehensive Clinical Nephrology, 6th edition, Elsevier(2019), section IV, p281

143. Agnes B. Fogo, Mark A. Lusco, Behzad Najafian and Charles E. Alpers: AJKD Atlas of Renal Pathology: Anti-Glomerular Basement Membrane Antibody-Mediated Glomerulonephritis. Am J Kidney Dis.2016;68(5):e29-e30.

144. Torres VE, Chapman AB, Devuyst O: Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 16;377(20):1930-1942, 2017. doi: 10.1056/NEJMoa1710030

145. Friedhelm Hildebrandt, Rannar Airik and John A. Sayer: Autosomal Dominant Polycystic Kidney Disease. Shrier’s Diseases of the Kidney, 9th edition, vol 1, Wolters Kluwer(2013): p501-518

146. Vicente E. Torres, Peter C. Harris: Autosomal Dominant Polycystic Kidney Disease. Comprehensive Clinical Nephrology, 6th edition, Elsevier (2019), section IX, p:532-543

147. Arlene B.Chapman, Olivier Devuyst, Kai-Uwe Eckardt, et al: Autosomal Dominant Polycystic Kidney Disease (ADPKD): Report from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference 2017.

148. KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International 2024, Vol 105 (6): S117-S314.

149. KDIGO 2024 Clinical Practice guidelines for the management of lupus nephritis. Kidney International (2024) 105 Suppl 1s, S1 - S69.

150. Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Kidney Int. 2024;105(3S):S71- S116.

151. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303

152. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190

153. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726